148 related articles for article (PubMed ID: 31499327)
21. Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines.
Fleury H; Carmona E; Morin VG; Meunier L; Masson JY; Tonin PN; Provencher D; Mes-Masson AM
Oncotarget; 2017 Jun; 8(25):40152-40168. PubMed ID: 27374179
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic exploitation of tumor cell defects in homologous recombination.
Powell SN; Kachnic LA
Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
[TBL] [Abstract][Full Text] [Related]
23. Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells.
Heyza JR; Arora S; Zhang H; Conner KL; Lei W; Floyd AM; Deshmukh RR; Sarver J; Trabbic CJ; Erhardt P; Chan TH; Dou QP; Patrick SM
Nutrients; 2018 Nov; 10(11):. PubMed ID: 30400270
[TBL] [Abstract][Full Text] [Related]
24. A truncated human xeroderma pigmentosum complementation group A protein expressed from an adenovirus sensitizes human tumor cells to ultraviolet light and cisplatin.
Rosenberg E; Taher MM; Kuemmerle NB; Farnsworth J; Valerie K
Cancer Res; 2001 Jan; 61(2):764-70. PubMed ID: 11212280
[TBL] [Abstract][Full Text] [Related]
25. Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.
Arora S; Heyza J; Zhang H; Kalman-Maltese V; Tillison K; Floyd AM; Chalfin EM; Bepler G; Patrick SM
Oncotarget; 2016 Nov; 7(46):75104-75117. PubMed ID: 27650543
[TBL] [Abstract][Full Text] [Related]
26. Nucleotide excision repair deficiency is intrinsic in sporadic stage I breast cancer.
Latimer JJ; Johnson JM; Kelly CM; Miles TD; Beaudry-Rodgers KA; Lalanne NA; Vogel VG; Kanbour-Shakir A; Kelley JL; Johnson RR; Grant SG
Proc Natl Acad Sci U S A; 2010 Dec; 107(50):21725-30. PubMed ID: 21118987
[TBL] [Abstract][Full Text] [Related]
27. Deficiency of nucleotide excision repair is associated with mutational signature observed in cancer.
Jager M; Blokzijl F; Kuijk E; Bertl J; Vougioukalaki M; Janssen R; Besselink N; Boymans S; de Ligt J; Pedersen JS; Hoeijmakers J; Pothof J; van Boxtel R; Cuppen E
Genome Res; 2019 Jul; 29(7):1067-1077. PubMed ID: 31221724
[TBL] [Abstract][Full Text] [Related]
28. Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells.
Soares DG; Machado MS; Rocca CJ; Poindessous V; Ouaret D; Sarasin A; Galmarini CM; Henriques JA; Escargueil AE; Larsen AK
Mol Cancer Ther; 2011 Aug; 10(8):1481-9. PubMed ID: 21622731
[TBL] [Abstract][Full Text] [Related]
29. DNA-repair genetic polymorphisms and breast cancer risk.
Smith TR; Levine EA; Perrier ND; Miller MS; Freimanis RI; Lohman K; Case LD; Xu J; Mohrenweiser HW; Hu JJ
Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1200-4. PubMed ID: 14652281
[TBL] [Abstract][Full Text] [Related]
30. The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells.
Chen P; Li J; Chen YC; Qian H; Chen YJ; Su JY; Wu M; Lan T
Cell Oncol (Dordr); 2016 Dec; 39(6):511-522. PubMed ID: 27473273
[TBL] [Abstract][Full Text] [Related]
31. miR‑138‑5p modulates the expression of excision repair cross‑complementing proteins ERCC1 and ERCC4, and regulates the sensitivity of gastric cancer cells to cisplatin.
Ning J; Jiao Y; Xie X; Deng X; Zhang Y; Yang Y; Zhao C; Wang H; Gu K
Oncol Rep; 2019 Feb; 41(2):1131-1139. PubMed ID: 30535472
[TBL] [Abstract][Full Text] [Related]
32. Expression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability.
Jordheim LP; Cros-Perrial E; Matera EL; Bouledrak K; Dumontet C
Clin Exp Pharmacol Physiol; 2014 Oct; 41(10):817-24. PubMed ID: 25115435
[TBL] [Abstract][Full Text] [Related]
33. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF.
Ferry KV; Hamilton TC; Johnson SW
Biochem Pharmacol; 2000 Nov; 60(9):1305-13. PubMed ID: 11008124
[TBL] [Abstract][Full Text] [Related]
34. Haploinsufficiency for BRCA1 is associated with normal levels of DNA nucleotide excision repair in breast tissue and blood lymphocytes.
Latimer JJ; Rubinstein WS; Johnson JM; Kanbour-Shakir A; Vogel VG; Grant SG
BMC Med Genet; 2005 Jun; 6():26. PubMed ID: 15955237
[TBL] [Abstract][Full Text] [Related]
35. New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy.
Gentile F; Tuszynski JA; Barakat KH
J Mol Graph Model; 2016 Apr; 65():71-82. PubMed ID: 26939044
[TBL] [Abstract][Full Text] [Related]
36. Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance.
Li W; Melton DW
Oncogene; 2012 May; 31(19):2412-22. PubMed ID: 21996734
[TBL] [Abstract][Full Text] [Related]
37. Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers.
Domagala P; Hybiak J; Rys J; Byrski T; Cybulski C; Lubinski J
Oncotarget; 2016 Oct; 7(42):68662-68673. PubMed ID: 27626685
[TBL] [Abstract][Full Text] [Related]
38. Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma.
Prosz A; Duan H; Tisza V; Sahgal P; Topka S; Klus GT; Börcsök J; Sztupinszki Z; Hanlon T; Diossy M; Vizkeleti L; Stormoen DR; Csabai I; Pappot H; Vijai J; Offit K; Ried T; Sethi N; Mouw KW; Spisak S; Pathania S; Szallasi Z
Sci Rep; 2023 Nov; 13(1):20567. PubMed ID: 37996508
[TBL] [Abstract][Full Text] [Related]
39. Regulation and disregulation of mammalian nucleotide excision repair: a pathway to nongermline breast carcinogenesis.
Latimer JJ; Majekwana VJ; Pabón-Padín YR; Pimpley MR; Grant SG
Photochem Photobiol; 2015; 91(2):493-500. PubMed ID: 25393451
[TBL] [Abstract][Full Text] [Related]
40. Regulators of global genome repair do not respond to DNA damaging therapy but correlate with survival in melanoma.
Bowden NA; Ashton KA; Vilain RE; Avery-Kiejda KA; Davey RJ; Murray HC; Budden T; Braye SG; Zhang XD; Hersey P; Scott RJ
PLoS One; 2013; 8(8):e70424. PubMed ID: 23940574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
